Meeting
2016 ASCO Annual Meeting
Final report of randomized phase II study of two different outpatient setting regimens, vinorelbine (VNR) with cyclophosphamide (CPA) and temozolomide (TMZ) with etoposide (VP).
Authors
Atsushi Ogawa
Niigata Cancer Center, Niigata, Japan
Atsushi Ogawa , Hiroshi Kawamoto , Mari Saito Oba , Ako Hosono , Yoshiyuki Kosaka , Junichi Hara , Yuji Ishida , Kenji Yamada , Katsuyoshi Koh , Yasuhiro Okamoto , Hideo Mugishima , Atsushi Kikuta , Takashi Taga
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
UMIN000003002
Citation
J Clin Oncol 34, 2016 (suppl; abstr 10550)
DOI
10.1200/JCO.2016.34.15_suppl.10550
Abstract #
10550
Poster Bd #
241
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
A combination chemotherapy, temozolomide (TMZ) with etoposide (VP), in relapsed or refractory pediatric solid cancer: Preliminary report of randomized phase II study of two different outpatient setting regimens (rPII).
First Author: Atsushi Ogawa
Poster
2021 ASCO Annual Meeting
A phase II study of anlotinib combined with STUPP regimen in the treatment of patients with newly diagnosed glioblastoma (GBM).
First Author: Peijing Li
Poster
2017 ASCO Annual Meeting
Activity of cabazitaxel in temozolomide refractory glioblastoma: Final results of a phase 2 study (C-GBM study; EudraCT 2013-001550-98 NCT 01866449).
First Author: Bernhard Heinrich
Poster
2013 ASCO Annual Meeting
A phase II study of oral metronomic combination therapy in relapsed epithelial ovarian cancer.
First Author: Sudeep Gupta